US approves vaccine to protect infants from respiratory syncytial virus – El Sol de Puebla

US authorities announce approval First vaccine to prevent disease caused by respiratory syncytial virus inside baby from birthso I know suitable for pregnant women.

pass a statementthe U.S. Food and Drug Administration (U.S. Food and Drug Administration, its English abbreviation) declared Approval of the drug Abrysvo and what it is used for Protect newborns from this virus until they are six months old.

About its application Approved for administration as a single-dose injection for Pregnant women between 32 and 36 weeks of gestation.

Prior to May FDA approves drug to prevent same diseasebut in his Apps for people 60 and over.

authorities detail The efficacy of the drug has been evaluated in international clinical studies This is ongoing, randomized and placebo-controlled.

In this regard, the study was approximately 3,500 pregnant women received Abriswar and others 3,500 pregnant women received placebo treatment.Those who have been vaccinated have been seen 81.8% lower risk of severe virus infection in the first 90 days of life and 64% within 180 days of birth.

inside another Subgroup of 3,000 pregnant women between 32 and 36 weeks’ gestationhalf received the vaccine and the rest received a placebo, the drug showed 34.7% reduction in virus risk and 91.1% reduction in severe risk within 90 days after at birth compared to placebo.

also details side effect The region with the highest number of reports among pregnant women is Headache, muscle pain, nausea, and pain at the injection site.

inside 1.8% women this dangerous hypertensive disorder, as. .and be known preeclampsia.At the same time, in the safety research, the proposed low birth weight and jaundice in babies higher proportion of women who has been vaccinated.

therefore, US Food and Drug Administration explain that in the prescribing information for the drug Abriswar A warning will be included that a problem has occurred. The imbalance in the proportion of preterm births among those receiving the drug was 5.7 percent This compared with 4.7 percent of patients who received a placebo.

FDA will also ask the company that made Abrysvo Post-Market Research to evaluate Signs of serious risk of preterm birth And evaluate for hypertensive disorders of pregnancy, including preeclampsia.

What should you know about respiratory syncytial virus?

he respiratory syncytial virus is a highly contagious virus that describes US Food and Drug Administrationby causing Respiratory infections in people of all ages.this is also Most Common Causes of Lower Respiratory Disease in Infants worldwide.

Because this condition is common in children, the Centers for Disease Control and Prevention (CDCits English abbreviation) means Almost all children get the virus by the age of two.

In most cases, symptoms of infection appear within four to six days of infection and are: runny nose, loss of appetite, coughing, sneezing, fever, and wheezing.In addition, in Babies also show other symptoms, such as fussiness, decreased activity, and trouble breathing.

when. . .when virus is serious this can be achieved Cause pneumonia, bronchitis and other diseasesalso Inflammation of the small airways of the lungs.inside Infants and children are at highest risk in the first year of life.

Source link

Leave a Comment